Stablepharma's SPVX02 Named TIME's Best Invention of 2026
News related to:Stablepharma · 1 min read
Stablepharma's SPVX02, a temperature-stable tetanus-diphtheria vaccine, has been named one of TIME's Best Inventions of 2026. This recognition highlights the significant strides the UK-based biotechnology company is making in overcoming one of healthcare's most persistent logistical challenges: the dependence on refrigeration for vaccine storage and distribution.
Developed using Stablepharma's proprietary StablevaX™ technology, SPVX02 is designed to remain stable at temperatures of 30°C for up to four years without refrigeration. This breakthrough eliminates the need for the cold chain, which has long been a hurdle in vaccine logistics and distribution, particularly in remote or resource-limited areas.
Professor Sir Jonathan Van-Tam, a former UK Deputy Chief Medical Officer and an Advisory Board Member of Stablepharma, emphasized the importance of this innovation.
SPVX02's inclusion in TIME's Best Inventions list underscores the global challenge Stablepharma is addressing. The vaccine has shown promising results in its Phase 1 clinical trial, published in eClinicalMedicine, part of The Lancet Discovery Science portfolio. The findings demonstrated the feasibility of reformulating an aluminium-adjuvanted vaccine into a fridge-free, freeze-resistant product without compromising safety or immunogenicity.
Ozgur Tuncer, Chief Executive Officer of Stablepharma, expressed the company's excitement at this recognition.
The company is advancing SPVX02 through a pivotal Phase 2b clinical trial. Beyond SPVX02, Stablepharma is applying its StablevaX™ platform to a growing pipeline of products, including anti-infectives, oncology therapies, and other medicines that currently require refrigerated storage and distribution. By reformulating refrigerated products into fridge-free versions, StablevaX™ offers pharmaceutical manufacturers new formulation options that could simplify distribution, reduce temperature-related product losses, and expand access to essential medicines.
TIME's annual Best Inventions list recognizes 300 innovations from around the world across sectors including healthcare, technology, and sustainability. The inclusion of SPVX02 highlights the importance of innovation that addresses real-world barriers to vaccine deployment and strengthens supply chains.
In summary, Stablepharma's SPVX02 vaccine, recognized as one of TIME's Best Inventions of 2026, represents a significant step towards simplifying vaccine logistics and improving access to temperature-sensitive medicines worldwide.